Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$144.95 - $152.29 $406,584 - $427,173
-2,805 Reduced 33.6%
5,544 $838,000
Q2 2022

Aug 12, 2022

SELL
$83.14 - $145.99 $5.95 Million - $10.4 Million
-71,523 Reduced 89.55%
8,349 $1.22 Million
Q1 2022

May 16, 2022

SELL
$110.08 - $142.92 $2.38 Million - $3.09 Million
-21,636 Reduced 21.31%
79,872 $9.47 Million
Q4 2021

Feb 14, 2022

SELL
$99.73 - $148.48 $167 Million - $249 Million
-1,675,910 Reduced 94.29%
101,508 $14 Million
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $34.2 Million - $48.1 Million
346,231 Added 24.19%
1,777,418 $247 Million
Q2 2021

Aug 16, 2021

BUY
$65.78 - $105.02 $19.5 Million - $31.1 Million
295,977 Added 26.07%
1,431,187 $139 Million
Q1 2021

May 13, 2021

BUY
$64.07 - $91.75 $8.79 Million - $12.6 Million
137,173 Added 13.74%
1,135,210 $77.6 Million
Q4 2020

Feb 09, 2021

SELL
$65.07 - $98.24 $4.37 Million - $6.59 Million
-67,086 Reduced 6.3%
998,037 $85.5 Million
Q3 2020

Nov 05, 2020

BUY
$59.04 - $77.95 $10.6 Million - $14 Million
179,306 Added 20.24%
1,065,123 $69.2 Million
Q2 2020

Aug 13, 2020

BUY
$29.01 - $74.23 $15.8 Million - $40.5 Million
546,031 Added 160.7%
885,817 $64.8 Million
Q1 2020

May 14, 2020

BUY
$27.51 - $57.29 $9.35 Million - $19.5 Million
339,786 New
339,786 $11.6 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.